Skeletal-related events in metastatic prostate cancer and the number needed to treat: A critical consideration

Urologia Internationalis

Volumn 90, Issue 3, 2013, Pages 329-333

  Schmitz Dräger, Bernd J ^a   Weiß, Claudia ^b   Ebert, Thomas ^a   Dörsam, Joachim ^a   Bismarck, Ekkehardt ^a  

^a Urologie   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Bisphosphonates; Denosumab; Number needed to treat; Prostate cancer; Risk benefit analysis; Zoledronic acid

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HYPOCALCEMIA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUMBER NEEDED TO TREAT; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS; SPINAL CORD COMPRESSION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84876848418     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000346387     Document Type: Article

References (14)

1. Thompson IM, Ankerst DP: Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176: 1853-1858.
2. Ward JF, Moul JW: Biochemical recurrence after definitive prostate cancer therapy. II. Treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol 2005; 15: 187-195.
3. Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G, Reventós J: Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003; 44: 661-665.
4. Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL: Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 2007; 14: 3551-3559.
5. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-444.
6. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K: Fracture risk in Danish men with prostate cancer: A nationwide register study. BJU Int 2007; 100: 749-754.
7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
8. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011; 377: 813-822.
9. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-1733.
10. Sur RL, Scales CD Jr, Preminger GM, Dahm P: Evidence-based medicine: A survey of American Urological Association members. J Urol 2006; 176: 1127-1134.
11. Common Terminology Criteria for Adverse Events Classification Version 4.0: http://ctep. cancer.gov/protocolDevelopment/electronic- applications/ctc.htm.
12. Breau RH, Fergusson D, Dahm P: Evidencebased urology in practice: number needed to treat. BJU Int 2009; 104: 6-8.
13. Miller K, Fizazi K, Smith M, Morote JP, Klotz L, Brown J, Tammela TLJ, Shore N, Ke C, Chung K, Goessl C: Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: A numberneeded-to-treat (NNT) analysis. 109th Meeting of the American Urological Association, Washington, 2011, A648.
14. Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011; 17: 621-643.